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Multifunctional adaptor protein APPL1 [adaptor protein contain-
ing PH (pleckstrin homology) domain, PTB (phosphotyrosine
binding) domain and leucine zipper motif] belongs to a growing
group of endocytic proteins which actively participate in various
stages of signalling pathways. Owing to its interaction with
the small GTPase Rab5, APPL1 localizes predominantly to
a subpopulation of early endosomes but is also capable of
nucleocytoplasmic shuttling. Among its various binding partners,
APPL1 was reported to associate with the nuclear co-repressor
complex NuRD (nucleosome remodelling and deacetylase),
containing both nucleosome remodelling and HDAC (histone
deacetylase) activities, but the biochemical basis or functional
relevance of this interaction remained unknown. Here we
characterized the binding between APPL1 and NuRD in
more detail, identifying HDAC2 as the key NuRD subunit
responsible for this association. APPL1 interacts with the
NuRD complex containing enzymatically active HDAC2 but not
HDAC1 as the only deacetylase. However, the cellular levels of
HDAC1 can regulate the extent of APPL1–NuRD interactions,
which in turn modulates the nucleocytoplasmic distribution of
APPL1. Increased binding of APPL1 to NuRD upon silencing
of HDAC1 promotes the nuclear localization of APPL1, whereas
HDAC1 overexpression exerts an opposite effect. Moreover,
we also uncovered a NuRD-independent interaction of APPL1
with HDAC1. APPL1 overexpression affects the composition
of the HDAC1-containing NuRD complex and the expression of
HDAC1 target p21
WAF1/CIP1. Cumulatively, these data reveal a
surprising complexity of APPL1 interactions with HDACs, with
functional consequences for the modulation of gene expression.
In a broader sense, these results contribute to an emerging theme
of endocytic proteins playing alternative roles in the cell nucleus.
Keywords:APPL1adaptorprotein,histonedeacetylase(HDAC),
multiprotein complex, nucleocytoplasmic shuttling, nucleosome
remodelling and deacetylase (NuRD) complex.
INTRODUCTION
During the last years many reports highlighted the impact of
endocytosis on cellular signalling (reviewed in [1–4]). On one
hand, endocytosis negatively regulates signal transduction by
downregulation and degradation of ligand–receptor complexes
from the plasma membrane, thus leading to signal attenuation.
On the other hand, endocytic trafﬁcking can also positively
contribute to signal propagation, as in several cases signalling
frominternalizedreceptorscontinuesintracellularlyinendosomal
compartments and certain signalling events require endocytosis
to occur [5,6]. Consistent with this idea, there is a growing list of
endocytic proteins actively participating in signal transduction.
Most of them are localized to the membranes of endosomal
compartments where they regulate the function of bona ﬁde
signalling proteins such as kinases, GTPases or transcription
factors [6]. Interestingly, several endocytic proteins are capable
of nuclear translocation themselves [7,8]. Although the exact
mechanisms and signiﬁcance of this phenomenon are largely
unknown, it seems that these endocytic proteins may interact
with nuclear molecules involved in transcription or chromatin
remodelling, changing their localization and/or activity and may
directly modulate the levels or speciﬁcity of gene transcription
[9–13]. Certain endocytic proteins translocate to the nucleus
in response to extracellular signals in order to exert a speciﬁc
biological effect, as reported for β-arrestin 1 [14] or for HIP1
(Huntingtin-interacting protein 1) [15]. However, in most cases it
is unclear to what extent the endocytic and nuclear functions are
related or exclusive for each compartment.
APPL1 [adaptor protein containing PH (pleckstrin homology)
domain, PTB (phosphotyrosine binding) domain and leucine
zipper motif] represents an interesting example of an endocytic
protein implicated in signal transduction and capable of nuclear
translocation. The structure of APPL1 (and of its less well-
characterizedhomologueAPPL2)comprisestheN-terminalBAR
(Bin1/amphiphysin/Rvs167) domain, followed by the PH and
the C-terminal PTB domain [16,17]. APPL1 is localized to the
membranes of a particular subpopulation of early endosomes,
where it is recruited via interaction with an active form of Rab5
GTPase, a key regulator of early steps of endocytosis [16].
In addition, APPL1 is present in the cytosol and to a lower
degree in the cell nucleus, despite the lack of a canonical NLS
(nuclear localization signal). APPL1 has been shown to interact
with many partners involved in various signalling pathways
mediating apoptosis [18], cell survival [19], cell proliferation and
chromatin remodelling [16]. In particular, APPL1 interacts with a
diverse set of receptors, including netrin-1 receptor DCC (deleted
in colorectal cancer) [18], nerve growth factor receptor TrkA
(tropomyosin receptor kinase A) [20,21], follicle-stimulating
hormone receptor [22,23] and the adiponectin receptors AdipoR1
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and AdipoR2 [24,25], as well as with signalling proteins: Akt
[17,23,26]; the p85 and p110 subunits of phosphatidylinositol-3
kinase [17,27]; OCRL (oculocerebrorenal syndrome of Lowe);
and inositol polyphosphate-5-phosphatase [28]. We have recently
shown that APPL1 protein binds Reptin, a transcriptional
repressor of the Wnt pathway and thus acts as a positive regulator
of β-catenin/TCF (T-cell factor)-dependent transcription [12]. In
general, APPL1 appears to play a role of an adaptor or a scaffold
protein for distinct signalling pathways.
Interestingly, it was previously documented that APPL1
interacts with the NuRD (nucleosome remodelling and deacetyl-
ase) complex [16]. This multiprotein co-repressor complex is
unique with respect to combining the two usually separate activ-
ities of chromatin remodelling and histone deacetylation in one
macromolecular assembly [29–32]. These activities are provided
by the nucleosome remodelling ATPase Mi-2 and two related
class I HDACs (histone deacetylases) HDAC1 and HDAC2.
The other complex components include histone-binding pro-
teins RbAp46 (retinoblastoma-associated protein 46; Rbbp7) and
RbAp48 (Rbbp4), one member of the MTA (metastasis tumour
antigen) family (alternatively MTA1, MTA2 or MTA3) [33], a
member of the MBD (methyl CpG-binding domain) family of
proteins (alternatively MBD2 or MBD3) [34] and transcriptional
repressors p66α (Gatad2A) and p66β (Gatad2B) interacting with
histones and MBD2/MBD3 [35,36]. Based on the number of
alternative subunits of this complex and their partially tissue-
speciﬁc expression, it was suggested that the NuRD complex
is, in fact, not a single molecular species but a set of distinct
althoughsimilarcomplexes,possiblyexhibitingpartlyspecialized
functions [37–39]. The main function of all NuRD complexes
is transcriptional repression, mediated by HDAC1 and HDAC2,
which are involved in deacetylation of histone H3 and H4 tails
[40]. Overall, NuRD regulates fundamental cellular processes
such as proliferation and differentiation and thus plays important
roles in development or carcinogenesis [33,41,42].
In the present study, we investigated the relationship between
the endocytic protein APPL1 and the NuRD complex in more
detail. First, we characterized the biochemical basis of this inter-
action and identiﬁed HDAC2 as a key NuRD subunit medi-
ating the association with APPL1. Moreover, we demonstrated
that binding to HDAC2-containing NuRD complex contributes
to the nuclear localization of APPL1. Interestingly, APPL1 is
also capable of forming another complex with HDAC1 which
seems independent of HDAC2-mediated association with NuRD.
Finally, our results suggest that APPL1 may regulate HDAC
functions,asAPPL1levelsinﬂuencetheexpressionoftheHDAC1
target p21
WAF1/CIP1.
EXPERIMENTAL
Cell lines
HEK-293 (human embryonic kidney 293) and A431 cells were
maintained in DMEM (Dulbecco’s modiﬁed Eagle’s medium)
supplemented with 10% fetal calf serum, 2 mM L-glutamine,
100 units/ml penicillin and 100 μg/ml streptomycin. HeLa cells
were grown in MEM (modiﬁed Eagle’s medium) supplemented
as above.
Plasmids
APPL1-encoding plasmids (pcDNA3/APPL1, pcDNA3/APPL1–
MYC, pGEX-6P-3/APPL1 amino acids 1–428, pGEX-6P-
3/APPL1 amino acids 429–709) were previously described in
[16]. C-terminally FLAG-tagged HDAC1 was recloned into
pcDNA3 (Invitrogen) from pBJ5-HDAC1–FLAG plasmid which
was a gift from Dr Stuart Schreiber (Broad Institute of Harvard
and MIT, Cambridge, MA, U.S.A.).
siRNA (small interfering RNA)
The following siRNA oligonucleotides were purchased from
Ambion: against HDAC1: a (ID # 120420), b (ID # 5436);
HDAC2: a (ID # 120209), b (ID # 120210); MTA2: a (ID #
5314), b (107516); RbAp46: a (ID # 121182), b (ID # 12277),
c (ID # 142450); RbAp48: a (ID # 16640), b (ID # 142862),
c (ID # 142863); and non-speciﬁc siRNA (negative control ID #
4611).
Production and puriﬁcation of short double-stranded RNA duplexes
Optimal esiRNA (endoribonuclease-prepared siRNA) target
regions with a length of 400–600 bp were selected using the
DEQOR web server (http://cluster-1.mpi-cbg.de/Deqor/deqor.
html). In brief, T7 promoter sequence was added to the selected
regions of APPL1 cDNAs by two PCRs: the ﬁrst PCR was
carried out by using gene-speciﬁc primer pairs that were
tagged at 5
  ends with a part of the T7 promoter (underlined).
During the second PCR, primers speciﬁc to T7 promoter were
used to amplify the whole T7 sequence. The sequences for
these primers are as follows: for APPL1, 5
 -TCACTATAGG-
GAGAGGATTCTCTTGTTGCCCCAGA-3
  (forward primer)
and 5
 -TCACTATAGGGAGACTCCCCCTCATTGTTTGACTC-
3
  (reverse primer); for T7 promoter, 5
 -GCTAATACGACTC-
ACTATAGGGAGAG-3
  (forward primer) and 5
 -GCTAATAC-
GACTCACTATAGGGAGAC-3
  (reverse primer). For control
luciferase esiRNA, the PCRs were performed in one step
using the following primers (T7 sequence underlined): luci-
ferase FLuc, 5
 -GCTAATACGACTCACTATAGGGAGAGG-
AGCAACTGCATAAGG-3
  (forward primer) and 5
 -GCTAAT-
ACGACTCACTATAGGGAGACAATCTGACGCAGGCAGT-
3
  (reverse primer) or RLuc, 5
 -GCTAATACGACTCACTAT-
AGGGAGAGGATAACTGGTCCGCAGTGGT-3
  (forward
primer) and 5
 -GCTAATACGACTCACTATAGGGAGACCCA-
TTCATCCCATGATTCAA-3
  (reverse primer). Further esiRNA
synthesis was carried out as described previously [43]. The con-
centration of esiRNA was determined by measuring the
absorbance at 260 nm.
Antibodies
The following antibodies were used: polyclonal against HDAC1
(Abcam), MTA2 (Oncogene), RbAp46 (Afﬁnity BioReagents),
EEA1 (early endosome antigen 1; BD Biosciences),
GAPDH (glyceraldehyde-3-phosphate dehydrogenase; Santa
Cruz Biotechnology), histone H3 (Sigma), histone H3 acetylated
on Lys
9 (Upstate), p21 (Santa Cruz Biotechnology) and APPL1
[16]; mouse monoclonal against HDAC1 (Abcam), HDAC2
(Upstate), RbAp48 (Upstate), FLAG-M2 (Sigma) and Myc
(Sigma); secondary horseradish peroxidase-conjugated goat anti-
mouse and anti-rabbit antibodies (Jackson ImmunoResearch),
Alexa Fluor® 488-conjugated anti-mouse and Alexa Fluor® 568-
conjugated anti-rabbit antibodies (Invitrogen).
Plasmid, siRNA and esiRNA transfection
For microscopy analysis, HeLa human cervical carcinoma cells
were transfected with 0.2 μg of plasmid DNA in 24-well plates
using FuGENE
TM reagent (Roche) and ﬁxed 48 h after transfec-
tion. HEK-293 cells used for immunoprecipitation or preparation
of nuclear/cytoplasmic fractions were transfected in 10 cm plates
with 18–24 μg of plasmid DNA using Lipofectamine
TM 2000
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(Invitrogen) and harvested 48 h after transfection. For siRNA
and esiRNA transfection, cells were transfected for 72 h with
10 nM siRNA or 33 nM esiRNA using HiPerFect transfection
reagent (Qiagen). All transfections were performed according to
the manufacturers’ instructions.
Western blot analysis
Cells were extracted in lysis buffer containing 1% Triton
X-100,0.1%SDS,5 μg/mlDNaseandproteaseinhibitorcocktail
(6 μg/ml chymostatin, 0.5 μg/ml leupeptin, 10 μg/ml anti-
pain, 2 μg/ml aprotinin, 0.7 μg/ml pepstatin A and 10 μg/ml
4-amidinophenylmethanesulfonylﬂuoridehydrochloride;Sigma)
in PBS. Samples of 10–20 μg total protein were subjected to
SDS/PAGE on 8, 10 or 12% polyacrylamide gels. Resolved
proteins were transferred to nitrocellulose membrane (Whatman)
for immunoblot analysis, probed with speciﬁc antibodies diluted
1:1000, and detected with enhanced chemiluminescence.
Preparation of nuclear/cytoplasmic fractions
HeLa cells were washed in ice-cold PBS, scraped from the
plate and centrifuged (800 g,3m i n ,4 ◦C). The cell pellet was
resuspended in a lysis buffer (10 mM Tris/HCl, pH 7.4, 10 mM
NaCl, 3 mM MgCl2,0 . 5% Nonidet P40 and protease inhibitors)
by passing 10 times through a pipette tip and then applied on
the top of 6 ml of sucrose buffer (0.7 M sucrose, 60 mM KCl,
15 mM NaCl, 15 mM Tris/HCl, pH 7.5, 2 mM EDTA, 0.5 mM
EGTA, 14 mM 2-mercaptoethanol and 0.1% Triton X-100).
After 10 min of centrifugation (1300 g,4 ◦C), the cytoplasmic
fraction was harvested from the top of the sucrose buffer, and
the nuclei forming a pellet at the bottom of the tube were
lysed in RIPA buffer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl,
0.5 mM EDTA, 1% Triton X-100, 0.5% deoxycholate, 0.1%
SDS, 5 μg/ml DNase and protease inhibitors) for 20 min on ice.
Both fractions were centrifuged for 15 min at 20000 g to remove
insoluble complexes. For HEK-293 cells, the above protocol
was modiﬁed to obtain clean fractions. HEK-293 cells were
trypsinized, centrifuged and resuspended in a buffer consisting
of 20 mM Hepes, pH 7.9, 20 mM NaF, 1 mM Na3VO4,1m M
Na3P2O7,1 mMEDTA,1 mMEGTA,1 mMDTT(dithiothreitol),
DNaseandproteaseinhibitorcocktail.After15 minoflysisonice,
Nonidet P40was addedto thecell extracts to aﬁnal concentration
of 0.2% for a further 15 min on ice. Afterwards cell lysates were
processed as above with centrifugation in the sucrose buffer. The
purity of fractions was tested by immunoblotting for EEA1 and
GAPDH as cytoplasmic markers and histone H3 as a nuclear
marker.
Immunoprecipitation and GST (glutathione transferase)
pull-down assay
APPL1, MTA2 or HDAC1 were immunoprecipitated from
HeLa or HEK-293 cells. First, cells were lysed in ice-
cold PBS containing 1% Triton X-100, 0.1% SDS, 5 μg/ml
DNase and protease inhibitor cocktail. Between 100 and
250 μg of protein was used per reaction. Proteins of interest
were immunoprecipitated by overnight incubation with an
appropriate antibody at 4◦C with constant rotation. Immune
complexes were recovered by 2 h incubation with Protein
G–agarose beads (Roche) at 4◦C with rotation, followed
by centrifugation and ﬁve washes in a wash buffer for
immunoprecipitation (50 mM Hepes, pH 7.5, 150 mM NaCl,
1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 10% glycerol,
5 μg/ml DNase and protease inhibitor cocktail). Next, samples
were incubated at 95◦C for 5 min with Laemmli buffer and
subjected to electrophoresis on 8% polyacrylamide gels. In some
experiments, antibodies were ﬁrst cross-linked with dimethyl
pimelimidate (Pierce) to Protein G agarose, incubated with
extracts or fractions at 4◦C overnight and washed extens-
ively with the wash buffer as described above. In such cases,
the ﬁnal elution was performed with 100 mM glycine, pH 2.5,
instead of Laemmli buffer.
GST, GST–APPL1-N (comprising 428 amino acids from
the N-terminus) and GST–APPL1-C (comprising amino acids
429–709) fusion proteins used in pull-down assays as bait
were expressed and puriﬁed according to the manufacturer’s
instructions (GE Healthcare). Isopropyl β-D-thiogalactoside
(Sigma) at a concentration of 0.5 mM was used to induce the
expression. In vitro translated HDAC1–FLAG, HDAC2, RbAp46
and RbAp48 proteins (synthesized using TNT T7 Coupled
Reticulocyte Lysate System from Promega according to the
manufacturer’s protocol) were incubated overnight at 4◦C with
constant rotation with equal amounts of glutathione–Sepharose
beads (GE Healthcare) complexed with GST, GST–APPL1-N
or GST–APPL1-C fusion proteins. Beads were washed 5 times
with the wash buffer used for immunoprecipitation. GST-fusion
proteins together with bound proteins were eluted with 10 mM
glutathione in 50 mM Tris/HCl, pH 8.0, for 15 min at room
temperature (22◦C) with shaking. Eluates were resuspended
in Laemmli buffer, subjected to SDS/PAGE (10% gels) and
immunoblotted for the proteins of interest.
HDAC activity assay
HDAC activity was measured using the HDAC Fluorimetric
Cellular Activity Assay kit according to the instructions from
the manufacturer (kit AK503 from BIOMOL). Brieﬂy, immuno-
precipitates bound to Protein G beads were washed three times
and resuspended in the assay buffer containing 100 μM substrate,
withorwithoutthepresenceof1 μMTSA(trichostatinA;Sigma)
or 1 mM nicotinamide (BIOMOL). The reaction mixtures were
incubated for 2 h at room temperature and stopped by adding
developer solution. The ﬂuorescence of the modiﬁed substrate
was measured after 30 min at 360 nm excitation/450 nm emission
using a spectroﬂuorophotometer (Shimadzu RF-530IPC).
Microscopy
HeLa cells grown on coverslips were washed twice in PBS
a n dﬁ x e dw i t h3 % paraformaldehyde in PBS for 15 min at
room temperature. Cells were then washed and permeabilized
in 0.1% Triton X-100 in PBS for 2 min at room temperature.
After washing, free aldehyde groups were quenched by 15 min
incubation with 50 mM NH4Cl in PBS. Washed coverslips were
blocked in 10% fetal bovine serum in PBS for 1 h, and incubated
with primary antibodies diluted in 5% fetal bovine serum. To
ensure a complete staining of nuclear proteins (HDAC2 and
APPL1), the incubation with primary antibodies was performed
overnight in a humid chamber. The coverslips were washed twice
for 5 min in PBS, and Alexa Fluor®-tagged secondary antibodies
were added for 2 h. Nuclei were visualized by adding Hoechst
reagent (Invitrogen) at a concentration of 1 μM to the secondary
antibody mix. The coverslips were washed three times in PBS,
rinsed in water, and mounted onto glass slides using Moviol
(Fluka). Images were acquired on a laser-scanning confocal
microscope Leica TCS SP2 with AOBS (acousto-optical beam
splitter). Cells were scanned along the z-axis in 1 μms t e p s .
Z-stacks were built and converted into maximal projections
using the Metamorph 4.6 r10 program (Universal Imaging).
Fluorescence intensity of APPL1 in the cell nuclei (manually
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outlined based on the Hoechst staining) was calculated using the
Metamorph 4.6 r10 program. Nuclear levels of APPL1 presented
as average pixel intensity reﬂect integrated pixel intensity divided
by the area of an outlined cell nucleus region. Results were calcu-
latedandstatisticalsigniﬁcancebetweengroupswasevaluatedby
GraphPad Prism 4.02 (GraphPad Software, Inc.). The presented
microscopy images were assembled using Adobe Photoshop 7.0.
RESULTS
Binding between APPL1 and the NuRD complex depends on HDAC2
In order to understand the biological signiﬁcance of interactions
between APPL1 protein and the multisubunit NuRD complex, we
started with the biochemical characterization of this association.
In particular, we set out to identify a subunit of NuRD respons-
ible for creating contact between APPL1 and the rest of the
multiprotein complex. To this end, we tested the ability of APPL1
to interact with the NuRD complex in lysates of cells depleted of
individualcomponentsofthecomplex(silencedoneatatime).We
reducedthelevelsoffourcoreNuRDsubunits:HDAC1,HDAC2,
RbAp48 or RbAp46, or additionally MTA2 protein (which
modulates the enzymatic activity of the HDAC core complex)
[44] by employing the RNAi (RNA interference) technique
with at least two different siRNA oligos per gene in HeLa
cells. Extracts from such cells were subjected to co-immunopre-
cipitation assay using anti-APPL1 antibody. As shown in Fig-
ure1(A),incellstransfectedwithnon-speciﬁcsiRNA,APPL1co-
immunoprecipitated with MTA2, HDAC1, HDAC2 and RbAp48
proteins, as previously reported [16]. In contrast, depletion of
HDAC2 precluded binding of APPL1 to the NuRD complex, as
shown by the lack of MTA2 and RbAp48 in the APPL1 immuno-
precipitatecomparedwithcontrolcells.ThedepletionofHDAC1,
RbAp48, RbAp46 or MTA2 did not disrupt the APPL1–NuRD
interactions, since other NuRD subunits were still present in
APPL1 immunoprecipitate under such conditions. Thus these
resultspointedoutthatHDAC2isacrucialcomponent,mediating
theAPPL1–NuRDinteraction.Interestingly,theabilityofAPPL1
to bind HDAC1 remained unaffected under conditions when
HDAC2 was depleted, and interactions with MTA2 and RbAp48
wereprohibited(Figure1A).Thisresultindicatedthat,inaddition
to HDAC2-mediated association with NuRD, APPL1 exhibits an
independent interaction with HDAC1 or an HDAC1-containing
complex which does not involve other core subunits of NuRD.
Strikingly, in cells silenced for HDAC1, the interactions between
APPL1 and the NuRD subunits were clearly enhanced, as
demonstrated by increased amounts of MTA2, HDAC2, RbAp48
and RbAp46 in APPL1 immunoprecipitates in comparison with
control cells (Figure 1A). This fact implies that lack of HDAC1
promotes binding of APPL1 to NuRD via HDAC2, further
pointing to the equilibrium between the amounts of complexes
containing APPL1–HDAC1 and APPL1–HDAC2–NuRD present
in cells under normal conditions.
In order to verify further that HDAC2 mediates the association
between APPL1 and NuRD, we tested whether the inability of
APPL1toassociatewithNuRDuponknockdownofHDAC2isnot
duetothedisruptionofinteractionsbetweenotherNuRDsubunits
under such conditions. To this end, we used extracts depleted
for HDAC1 or HDAC2 and performed co-immunoprecipitation
experiments with anti-MTA2 or anti-HDAC1 antibodies. As
shown in Figure 1(B), lack of HDAC2 did not preclude the
interactions between the remaining NuRD subunits (HDAC1,
MTA2, RbAp46 and RbAp48). These results demonstrate that
lack of HDAC2 does not affect the overall integrity of the NuRD
complex,butspeciﬁcallypreventsthebindingbetweenNuRDand
Figure 1 HDAC2 is critical for binding of APPL1 to the NuRD complex
(A and B) Extracts from HeLa cells transfected for 72h with two (a, b) or three (a, b, c) different
siRNA oligonucleotides per gene against: HDAC1, HDAC2, MTA2, RbAp48 and RbAp46 or
non-speciﬁc siRNA ( ) were subjected to immunoprecipitation (IP) using: (A) anti-APPL1
antibody;(B)anti-HDAC1antibody(leftpanel)oranti-MTA2antibody(rightpanel).Non-speciﬁc
antibodies (IgG) were used as controls. Input indicates 10% of total cell extracts used for
immunoprecipitation.ImmunoprecipitatesandinputextractswereanalysedbyWesternblotting
using different antibodies as indicated. (C) To verify the direct interactions between APPL1 and
HDAC1 or HDAC2, in vitro translated HDAC1–FLAG and untagged HDAC2 were subjected to
GSTpull-downassayusingGSTalone( )orGSTfusedtotheN-orC-terminalpartsofAPPL1
(APPL1-N or APPL1-C, respectively). Input indicates 10% of in vitro translated material used
for the pull-down assay. Bound proteins were analysed by Western blotting using anti-HDAC1
and anti-HDAC2 antibodies. ND, not determined.
APPL1, further conﬁrming that HDAC2 mediates the APPL1–
NuRD interactions. We next wished to test whether APPL1 was
able to bind directly to HDAC2. To this end, we conducted GST
pull-down experiments with in vitro translated HDAC2 using as
bait two non-overlapping fragments of APPL1 fused to GST:
the N-terminal part (amino acids 1–428; comprising the BAR
and PH domains) and the C-terminal part (amino acids 429–709;
containingthePTBdomain).Wecoulddetectweakdirectbinding
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of HDAC2 to the N-terminal part of APPL1 (Figure 1C). These
resultscouldpotentiallyexplaintheroleofHDAC2inbridgingthe
association between APPL1 and NuRD; however, most likely,
thebindingofHDAC2toAPPL1ismoreefﬁcientwhenHDAC2is
presentinthecontextofthewholeNuRDcomplex.Inaddition,we
performed similar experiments with in vitro translated HDAC1,
RbAp46 and RbAp48 proteins. Although no binding to APPL1
wasdetectedforRbAp46andRbAp48(whichweredemonstrated
not to be critical for APPL1–NuRD interactions; results not
shown), HDAC1 appeared to weakly interact with both N- and
C-terminal parts of APPL1 (Figure 1C). These data suggest that
HDAC1 and HDAC2 may share a binding site in the N-terminal
partofAPPL1,whereasHDAC1canadditionallyinteractwiththe
C-terminus of APPL1. The ability of APPL1 to interact directly
with HDAC1 can explain the binding between these proteins,
which is independent of HDAC2. Cumulatively, these ﬁndings
demonstrated that APPL1 interacts with the NuRD complex via
HDAC2 and forms another complex with HDAC1.
HDAC2-dependent interactions between APPL1 and NuRD occur in
both the cytoplasmic and nuclear fractions, also in the presence of
HDAC inhibitors
The initial data demonstrating the binding between APPL1 and
NuRD came from experiments using HeLa nuclear extracts [16].
Although the NuRD components are considered to be largely
nuclear proteins, no comprehensive analysis of their intracellular
distribution has been performed, even though some of them were
reported to also be present, to different degrees, in the cytoplasm
[45,46]. In order to address the question of the intracellular local-
ization of the APPL1–NuRD interaction, ﬁrst we systematically
investigated the distribution of the individual NuRD subunits
in the cell. Fractionation experiments from different cell lines
presented in Figure 2(A) revealed that most NuRD subunits
are predominantly nuclear but their cytoplasmic pools are also
signiﬁcant in several cases, particularly for RbAp46 (but not
related RbAp48), HDAC1 and HDAC2. Different proportions of
various NuRD subunits found in the nucleus and in the cytoplasm
argue that these proteins are not exclusively complexed to
eachotherbutarealsopresentfreeorascomponentsofcomplexes
other than NuRD. Interestingly, the cytoplasmic pools of the
NuRDcomponentsappeargenerallylargerinHeLaandHEK-293
than in A431 cells, which may imply some kind of physiological
relevance depending on the cell type. Our observation of
cytoplasmic pools of HDAC1 and HDAC2 is in agreement with
other studies demonstrating that the NuRD components can form
complexes with cytoplasmic proteins [e.g. HDAC2 with IRS-1
(insulinreceptorsubstrate1)][46].Thesetwofactspromptedusto
investigate the intracellular site of APPL1–NuRD interaction. As
shown in Figure 2(B), APPL1 co-immunoprecipitates the NuRD
components from both cytoplasmic and nuclear fractions. In both
compartments, these interactions are HDAC2-dependent, as they
were clearly reduced upon HDAC2 knockdown. Cumulatively,
these results clearly demonstrate that APPL1 can interact with
the NuRD components both in the nucleus and in the cytoplasm.
Since APPL1 binds the NuRD complex in a strictly HDAC2-
dependent manner, we could consider two, non-mutually exclus-
ive, explanations for this dependence. In one case, the enzymatic
activity of HDAC2, and in the other case its physical presence
couldbecrucialforAPPL1–NuRDbinding.Toaddressthisissue,
we conducted co-immunoprecipitation experiments using anti-
APPL1 antibody in nuclear and cytoplasmic fractions of HeLa
cells pretreated with the HDAC class I and II inhibitors, TSA or
sodium butyrate. Both treatments caused a large increase in the
levelsofacetylatedhistoneH3,asdeterminedbyWesternblotting
(results not shown). The formation of the NuRD complex under
suchconditionswascontrolledbyimmunoprecipitationwithanti-
MTA2 antibody. As depicted in Figure 2(C), the APPL1–NuRD
associationsininhibitor-treatedcellsaregenerallypreserved,with
only minor effects. Sodium butyrate treatment leads to a slight
reduction in APPL1 interactions with the HDAC2-containing
complex, as well as with HDAC1 in the cytoplasm. In TSA-
treated cells, only the interactions of APPL1 with HDAC1 in the
cytoplasmic fraction were slightly reduced. The observed effects
were speciﬁc for APPL1 interactions, since MTA2 association
withtheNuRDsubunitsremainedunchangedupontreatmentwith
HDAC inhibitors (Figure 2C). Moreover, in nuclear fractions, the
reduction of HDAC enzymatic activity by either TSA or sodium
butyrate enhanced the binding of APPL1 to HDAC1, without
affectingtheassociationwithNuRD.Inconclusion,theenzymatic
activity of HDAC1 or HDAC2 seems not to have a critical
role for APPL1–NuRD interactions, even though it may slightly
modulate them depending on the intracellular compartment. As
there are many examples of non-histone proteins being targets for
HDAC enzymatic activities (reviewed in [47]), we also tested if
APPL1 was acetylated. By probing APPL1 immunoprecipitates
with antibodies against acetylated lysine residues, we were not
able to detect modiﬁcation of APPL1, even upon treatment with
HDAC inhibitors (results not shown), further indicating that the
interactions between APPL1 and HDAC1 or HDAC2 are unlikely
to have a substrate–enzyme character.
Interactions with the NuRD complex promote the nuclear
localization of APPL
Knowing that APPL1 binds the NuRD components in both cyto-
plasmic and nuclear fractions in an HDAC2-dependent manner,
we attempted to investigate whether these interactions played a
role in regulating the nucleocytoplasmic distribution of APPL1.
APPL1 lacks a classical NLS, and the mechanism of its nuclear
targeting is unknown. There are reported examples of endocytic
proteins which are imported to the nucleus via interactions with
anNLS-harbouringpartner(reviewedin[7]).Despitethefactthat
wefoundsomeNuRDcomponentsinthecytoplasm,thiscomplex
still remains mainly nuclear. We therefore hypothesized that
an increased interaction of APPL1 with NuRD (observed upon
HDAC1 silencing, Figure 1A) could result in an enhancement
of the nuclear localization of APPL1, whereas lack of such
interactionsuponknockdownofHDAC2couldreducethenuclear
presence of APPL1. We ﬁrst veriﬁed that the total intracellular
levelsofAPPL1proteinwerenotaffectedbysilencingofHDAC1
or HDAC2 (Figure 3A) or both together (results not shown), or
by overexpression of HDAC1 or HDAC2 (Figure 3A). We then
downregulated the levels of HDAC1 or HDAC2 by RNAi in
HeLa cells and measured the amounts of APPL1 present in the
cell nucleus by quantitative microscopy. Consistent with the bio-
chemical experiments demonstrating the opposite effects of
HDAC1 and HDAC2 depletion on the extent of APPL1–
NuRD interaction (Figure 1A), we observed that knockdown
of HDAC2 reduces the nuclear localization of APPL1 by
approx. 20%, whereas knockdown of HDAC1 enhances it by at
least 30% (Figure 3B). These data indicate that binding of
APPL1toHDAC2-containingNuRDcomplexfavoursthenuclear
localization of APPL1. Moreover, the overexpression of HDAC1
exerts an effect opposite to the knockdown of HDAC1, leading
to the approx. 20% reduction in the nuclear localization of
APPL1(Figure3C).Toexplainthisphenomenon,weinvestigated
the extent of interactions between APPL1 and the NuRD
complex subunits upon HDAC1 overexpression and observed a
decreaseinAPPL1interactionswithHDAC2,RbAp48andMTA2
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Figure 2 APPL1 interacts with the NuRD subunits in both cytoplasmic and nuclear fractions independently of HDAC enzymatic activity
(A) Cytoplasmic (C) and nuclear (N) fractions along with total extracts (T) of three different cell lines, HeLa, HEK-293 and A431, were analysed for the presence of several NuRD subunits by Western
blotting with different antibodies as indicated. For detection with a given antibody, equal amounts of proteins from all fractions and three cell lines were loaded (20μg of protein for blotting with
anti-p66α/β, -MBD2/3 and -EEA1 antibodies; 15μg of protein for anti-APPL1, -HDAC2, -RbAp46 and -GAPDH; 10μg of protein for anti-MTA2, -HDAC1, -RbAp48 and -Histone H3; the different
amounts of protein loaded were chosen to match different sensitivities of the antibodies used). Cytoplasmic (GAPDH and EEA1) and nuclear (histone H3) markers were used to demonstrate the
purity of fractions. (B) HeLa cells were transfected for 72h with two oligonucleotides (a, b) against HDAC2 or with non-speciﬁc control oligonucleotide ( ). Cytoplasmic and nuclear fractions were
prepared and subjected to immunoprecipitation (IP) using anti-APPL1 antibody or non-speciﬁc immunoglobulins (IgG). Immunoprecipitates were tested for the presence of several NuRD subunits
by immunoblotting with various antibodies as indicated. Right panel: 10% of the input material (cytoplasmic and nuclear fractions) were analysed for the knockdown efﬁciency using anti-HDAC1
and anti-HDAC2 antibodies, as well as for the fraction purity with anti-GAPDH and anti-histone H3 antibodies. (C) Immunoprecipitation from cytoplasmic (C) or nuclear (N) fractions of HeLa cells
treated for 20h with 100ng/ml of TSA (left panel) or 25mM sodium butyrate (BUT; right panel) was performed using anti-APPL1, anti-MTA2 or non-speciﬁc rabbit IgG. Precipitates along with 10%
of the input material were analysed by Western blotting using different antibodies, as indicated. Ctr, control.
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(Figure 3D). The observed destabilization of association between
APPL1 and HDAC2-containing NuRD complex upon HDAC1
overexpression could explain the reduced nuclear localization
of APPL1. These results, in combination with the results
demonstrating the increase in APPL1–NuRD interactions upon
HDAC1 silencing (Figure 1A), clearly show that the intracellular
level of HDAC1 inﬂuences the extent of binding between
APPL1andtheHDAC2-containingNuRDcomplex.Interestingly,
HDAC2 overexpression did not enhance the interactions between
APPL1 and the HDAC2-containing NuRD complex, as tested by
immunoprecipitationand,consequently,nochangesinthenuclear
localizationofAPPL1wereobserved(resultsnotshown).Overall,
the extent of interactions with the NuRD complex appears to
be modulated by HDAC1 and to regulate the nucleocytoplasmic
distribution of APPL1.
APPL1-bound HDAC2 exhibits enzymatic activity
Having established the importance of HDAC2-mediated
interactions with NuRD for the nuclear localization of APPL1,
we next investigated whether APPL1can inﬂuenceany properties
oftheNuRDcomplexoritscomponents.First,westudiedwhether
APPL1 associates with enzymatically active HDAC. To this
end, we employed enzymatic assays with a ﬂuorogenic substrate
and demonstrated that the immunoprecipitates of APPL1 exhibit
deacetylaseactivitysensitivetotheclassI/IIHDACinhibitorTSA
(Figure 4A). This enzymatic activity is not affected by the class
III HDAC inhibitor nicotinamide, conﬁrming that APPL1 binds
to active class I enzymes, such as HDAC1 or HDAC2. We further
wishedtodeterminewhetherbothHDAC1andHDAC2contribute
to APPL1-associated deacetylase activity. We observed that this
activity was signiﬁcantly inhibited upon knockdown of HDAC2
and only slightly reduced upon silencing of another NuRD sub-
unit, MTA2 (Figure 4B). Interestingly, in HDAC1-depleted HeLa
cells, deacetylase activity bound to APPL1 was considerably
increased, which could be explained by an enhanced binding of
HDAC2 and NuRD to APPL1 under such conditions (Figure 1A).
This fact strongly implies that most of the deacetylase activity
found in the APPL1 complex is derived from HDAC2, whereas
HDAC1associatedtoAPPL1seemstobelessactiveorlessabund-
antthanHDAC2.TheseresultsconﬁrmthatAPPL1interactswith
the NuRD complex containing enzymatically active HDAC2.
APPL1 overexpression affects the composition of
HDAC1-containing NuRD complex and the expression of HDAC1
target p21WAF1/CIP
We tested further whether overexpression of APPL1 could affect
the overall activity of HDAC1 or HDAC2, or their ability to bind
with other NuRD subunits. No signiﬁcant changes were observed
in the enzymatic activities of HDAC1 or HDAC2 immunoprecip-
itated from cells silenced for or overproducing APPL1, as mea-
sured in vitro using a ﬂuorogenic substrate (results not shown).
Instead, overexpression of APPL1 appeared to modulate the
amounts of NuRD components interacting with HDAC1, without
affecting their overall intracellular levels (Figure 5A). Immuno-
precipitates of HDAC1 from cells overproducing APPL1 con-
tained reduced amounts of MTA2 and HDAC2, and occasionally
also of RbAp48. This effect correlated with the levels of APPL1
and was stronger upon its higher overexpression (Figure 5A).
Similar reduction of the NuRD components associated with
HDAC1 was observed when HDAC1 immunoprecipitates were
isolatedfromthenuclearfractionsofcellsoverexpressingAPPL1
(Figure 5B). In contrast, the composition and amounts of proteins
present in HDAC2 immunoprecipitates were not altered upon
APPL1 overexpression (results not shown). These data indicate
that an excess of APPL1 speciﬁcally affects the assembly of
HDAC1-containingNuRDcomplexbutnotoftheNuRDcomplex
containing HDAC2, possibly by competing out some of the
HDAC1-binding proteins from their complex with HDAC1.
In order to verify whether the observed changes in the inter-
actionstatusofHDAC1mayhaveanyrelevancefortheexpression
of HDAC1 targets in vivo, we investigated the levels of the
cyclin-dependent kinase inhibitor p21
WAF1/CIP1. In proliferating
cells, HDAC1 is bound directly to the promoter of p21
WAF1/CIP1
repressingitstranscription,whereasinHDAC1knockoutcells,the
p21
WAF1/CIP1 expression is upregulated and these changes cannot
be compensated by the increased levels of HDAC2 present in
these cells [40,48]. Strikingly, the cellular amounts of p21
WAF1/CIP1
were increased upon overexpression of two different constructs
of APPL1 in HEK-293 cells (Figure 5C). This effect was speciﬁc
for p21
WAF1/CIP1, as the levels of Myc, another proliferation-related
protein reported to exhibit increased expression upon HDAC1
silencing [49], were not changed. We could further conﬁrm that
the downregulation of APPL1 by esiRNA caused an opposite
effect, namely a decrease in p21
WAF1/CIP1 protein levels, in both
HEK-293 and HeLa cells (Figure 5C). These data demonstrate
that APPL1 can selectively modulate the expression of HDAC1
targets.
DISCUSSION
In the present study, we characterized the interactions between an
endocytic adaptor APPL1 and the NuRD co-repressor complex.
We provide evidence that binding between NuRD and APPL1
involves HDAC2, although APPL1 can also associate with
HDAC1 in a NuRD-independent manner. Overall, our results
point to a complexity of interactions between APPL1 and HDAC-
containing complexes, which appear to regulate APPL1 nuclear
localization and HDAC function. APPL1 belongs to a growing
group of endocytic proteins which undergo nucleocytoplasmic
shuttling, interact with nuclear partners and affect their functions,
thus modulating gene expression.
APPL1 interaction with the NuRD complex depends on HDAC2
Here we have extended our previous studies which demonstrated
an interaction of APPL1 protein with the core subunits of the
NuRD complex such as HDAC1, HDAC2, RbAp46, RbAp48 and
MTA2 [16]. In the present work, we identify HDAC2 as a key
subunitwhichbridgesthebindingofAPPL1toNuRDandisindis-
pensable for this association. Interestingly, HDAC1 cannot com-
pensateforlackofHDAC2insupportingtheinteractionofAPPL1
with NuRD, which strongly argues for their non-redundant roles
within the NuRD complex. HDAC1 and HDAC2 are highly
homologous proteins found, apart from NuRD [29,31,32], also in
other multiprotein complexes such as Sin3 [50–52] or CoREST
[45]. Importantly, it has been reported that NuRD as well
as CoREST complexes may exist as entities containing either
HDAC1 or HDAC2 or both [45]. Our results from the present
study support this conclusion, as we show that APPL1 interacts
with the NuRD complex containing HDAC2 (and possibly with
the complex including both HDAC1 and HDAC2), but not
with the NuRD complex comprising HDAC1 as the only
deacetylase. The exact basis for this binding selectivity or for
the functional differences between various NuRD variants is
unknown. Despite high homology and common appearance in
several complexes, the two deacetylase enzymes are not function-
ally redundant, as shown by an embryonic lethality of HDAC1
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Figure 3 The interactions with NuRD affect cellular distribution of APPL1
(A) APPL1 protein levels do not depend on HDAC1 or HDAC2. Extracts of HeLa cells with reduced HDAC1 or HDAC2 levels by siRNA [two different oligonucleotides (a, b) per gene or non-speciﬁc
oligo ( ), transfected for 72h; top panel] and HEK-293 cells transfected for 48h with plasmids encoding FLAG-tagged HDAC1 (pHDAC1–FLAG), HDAC2 (pHDAC2–FLAG) or with a control vector
(bottompanel),wereanalysedbyWesternblottingusinganti-APPL1antibodies.Todemonstratetheefﬁciencyofsilencingoroverexpression,extractswereprobedusinganti-HDAC1andanti-HDAC2
antibodies. GAPDH was included as a loading control. (B) Microscopy-based analysis of APPL1 nuclear localization upon silencing of HDAC1 or HDAC2. HeLa cells were transfected with siRNA
oligonucleotides: one non-speciﬁc ( ) and two speciﬁc per gene (a and b) against HDAC1 and HDAC2 for 72h, followed by ﬁxation and immunostaining for APPL1. Acquired microscopic images
were analysed by Metamorph software and the average pixel intensities corresponding to APPL1 in the nuclei (as visualized by Hoechst staining, not shown) were calculated. The results of a
representative experiment are shown in the graph. The values are normalized with respect to the average pixel intensity of nuclear APPL1 in cells transfected with non-speciﬁc siRNA, assigned one
arbitrary unit. Error bars indicate standard error (minimum 100 cells from each transfection were used for the analysis). The results were statistically analysed by GraphPad Prism4 software, and the
values obtained for each knockdown experiment were signiﬁcantly different from the control at P <0.0001. The images demonstrate the cellular localization of APPL1 upon silencing of HDAC1 or
HDAC2 (as indicated) and represent a maximal projection of z-stacks. Scale bar: 24μm. (C) HeLa cells transfected with the plasmid encoding FLAG-tagged HDAC1 (pHDAC1–FLAG) were analysed
with respect to the nuclear localization of APPL1 as described above. Untransfected cells (marked with asterisks) were used as a control (the average pixel intensity of nuclear APPL1 set to one unit).
The statistical analysis was performed on 50 transfected and 50 untransfected cells, and the difference between them was statistically signiﬁcant at P <0.0001. The images represent a maximal
projection of z-stacks. FLAG staining (left image) is shown to discriminate between transfected and untransfected cells with respect to APPL1 staining (right image). Scale bar: 24μm. (D) HDAC1
overexpression leads to the destabilization of binding between APPL1 and HDAC2-containing NuRD complex. Extracts of HEK-293 cells transfected with HDAC1-FLAG or with a control vector were
subjected to immunoprecipitation (IP) with anti-APPL1 or non-speciﬁc (IgG) antibodies. Immunoprecipitates, along with 10% of the extracts used (input), were analysed by Western blotting using
the indicated antibodies. MW indicates a lane loaded with a molecular mass (weight) marker. Two exposures (short and long) of the HDAC1 blot are shown. Overexpressed HDAC1 exhibits some
non-speciﬁc binding to IgG-covered protein G beads (visible at the long exposure of the blot and marked with an asterisk); however, its binding to beads containing anti-APPL1 antibodies is higher.
knockout mice in which an increased expression of HDAC2 and
HDAC3 cannot compensate for lack of HDAC1 [40]. One sur-
prisingaspectofourpresentstudyistheobservationthattheextent
of HDAC2-mediated association between APPL1 and NuRD is
regulated by the intracellular levels of HDAC1, pointing to a
tightly controlled equilibrium between the interactions exhibited
by both HDACs. This picture is further complicated by the
fact that APPL1 is also found in complex with HDAC1, which
occurs independently of HDAC2 or other NuRD components.
This association probably reﬂects an interaction of APPL1 with
Reptin, a transcriptional repressor acting in the Wnt/β-catenin
pathway and capable of binding HDAC1 [12]. We have recently
shown that the presence of APPL1 in a complex containing
β-catenin, Reptin and HDAC1 is important for the modulation
of β-catenin/TCF-dependent transcription [12]. Here we demon-
strate that, in agreement with the immunoprecipitation data
obtained from cell extracts, in vitro translated HDAC1 and
HDAC2 deacetylases both exhibit a weak direct binding to
recombinant APPL1 via its N-terminus, and in case of HDAC1
also via the C-terminus of APPL1, indicating that interactions of
APPL1 with both deacetylases may be mechanistically different.
In general, recombinant HDAC1 and HDAC2 are difﬁcult to
express and have little enzymatic activity, which can be restored
uponco-expressionofRbAp46,RbAp48andMTA2thatappearto
stabilize proper folding of HDAC1/2 [44,45,53]. In this light, the
weak direct interactions between APPL1 and HDAC1/2 in vitro
may not be surprising, although the associations in the context of
other cellular proteins seem to be reasonably efﬁcient.
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Figure 4 Deacetylase activity detected in APPL1 complexes derives mainly from HDAC2
HDAC enzymatic activity was measured using a ﬂuorimetric method (as described in the Experimental section) in immunoprecipitates from HeLa cells. (A) APPL1 binds active HDACs from class I or
II.TheAPPL1immunoprecipitate(IP)wasdividedintothreeequalparts:oneleftuntreatedandtheothertwotreatedwithHDACinhibitors:1 mMnicotinamideand1μMTSA.Non-speciﬁcrabbitIgG
wasusedasacont rol .(B) HeLacellsweresilencedfor HDAC1,HDAC2andMTA2 [usingtwo (a,b)different siRNAoligonucleotidesper geneornon-speciﬁcsiRNA ] priorto immunoprecipitation
using APPL1 antibodies or non-speciﬁc rabbit IgG. The same extracts as presented in Figure 1(A) were used (one third of the immunoprecipitates was measured in the HDAC activity assay, two
thirds blotted as shown in Figure 1A). The intensity of ﬂuorescence emitted by the deacetylated substrate is expressed in arbitrary units in (A)a n d( B).
The signiﬁcance of APPL1 interactions with HDACs
Another important ﬁnding of our study are the differences
in enzymatic activity of HDACs associated with APPL1. Our
analysis revealed that deacetylase activity in APPL1 immunopre-
cipitateswaslargelyderivedfromHDAC2,indicatingthatAPPL1
associates with the active NuRD complex, whereas HDAC1
bound to APPL1 is less active or inactive. The experiments
using HDAC inhibitors did not reveal signiﬁcant changes in
the amounts of HDAC1 or HDAC2 bound to APPL1, thus it
is unlikely that APPL1 preferentially associates with inhibited or
activated enzymes. Furthermore, we could not detect any changes
intheglobaldeacetylaseactivityofHDAC1-orHDAC2-immuno-
precipitates from extracts of cells overexpressing or silenced for
APPL1, arguing that APPL1 itself does not change the enzymatic
propertiesofHDACs,asmeasuredusingartiﬁcialsubstrates.This
is not surprising, considering that APPL1 is not a stoichiometric
component of the NuRD complex, and APPL1-bound pools of
HDAC2 or HDAC1 constitute only a minor fraction of their total
cellularcontent,arguingfortheirﬁne-tuningregulatorycharacter.
Although we were unable to detect any measurable changes
in the properties of HDAC2-containing NuRD complex upon
alterationsofAPPL1levelsincells,wecouldneverthelessobserve
the impact of APPL1 on the interactions exhibited by HDAC1.
Overexpression of APPL1 reduced the binding of HDAC1 with
the other core NuRD subunits and further correlated in vivo
with the increased expression of p21
WAF1/CIP1, a gene speciﬁcally
repressed by HDAC1 under normal conditions. Silencing of
APPL1 evoked an opposite effect and resulted in reduced
expression of p21
WAF1/CIP1. These results suggest that increased
APPL1 levels negatively modulate the repressor potential of
HDAC1, indicating that APPL1 might act as a sequestering factor
for HDAC1 to restrict its function in vivo. We have recently
shown that overexpression of APPL1 reduces the amounts of
HDAC1, HDAC2 and β-catenin associated with Reptin and
decreases the levels of Reptin and HDAC1 on the promoters of
β-catenin target genes, thereby stimulating β-catenin/TCF-
mediated transcription by relieving Reptin-dependent repression
[12]. Thus, APPL1 could indeed modulate the composition
and activity of various complexes containing HDACs. HDACs
themselves do not bind DNA and are usually recruited to their
histone substrates by sequence-speciﬁc DNA-binding proteins
[41], therefore their action is regulated by various protein–protein
interactions. By reducing the binding of HDAC1 to other NuRD
components, overexpressed APPL1 may reduce the enzymatic
activity of HDAC1 and/or affect its potential to be recruited to
DNA. Indeed, our results showing low enzymatic activity of
HDAC1 bound to APPL1 suggests that this pool of HDAC1 is
sequestered and lacks other interacting partners, which ensures
its proper conformation and thus activity (see above) [44,45,53].
The role of NuRD in mediating the nuclear localization of APPL1
One of the main questions regarding the endocytic proteins acting
inthecellnucleusisthemechanismoftheirnucleartranslocation.
SomeofsuchendocyticadaptorspossessclassicalNLSs,whereas
others enter the nucleus via interactions with NLS-harbouring
partners [7]. APPL1 lacks a canonical NLS, and its nuclear
translocation must occur via the latter piggy-back mechanism.
An analogous phenomenon was reported for endosomal adaptors
such as Epsin1, which binds PLZF (promyelocytic leukemia
zinc ﬁnger) transcription factor [54], or for CALM (clathrin
assembly lymphoid myeloid leukemia) which associates with a
transcriptional regulator CATS (CALM interactor expressed in
thymus and spleen) in order to translocate to the nucleus [55].
In the present study, we identiﬁed a similar mechanism operating
for APPL1 and uncovered the role of HDAC2-containing NuRD
complexes in mediating APPL1 nuclear localization. The compo-
nents of NuRD are predominantly nuclear, although according
to our systematic analysis of their cellular localization, some
components are also present in the cytoplasm, and the APPL1–
NuRD interactions are detected in both the nuclear and cyto-
plasmic fractions. However, we observed that the increased
association between APPL1 and NuRD occurring upon silencing
of HDAC1 results in a higher accumulation of APPL1 in the
nucleus. In contrast, when the APPL1–NuRD interactions are
destabilized upon HDAC2 knockdown or HDAC1 overexpres-
sion, the nuclear levels of APPL1 are diminished. These results
argue that the interactions with the NuRD complex favour the
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Figure 5 APPL1 overexpression affects the composition of HDAC1-
containing NuRD complex and the expression of HDAC1 target p21WAF1/CIP
(A) APPL1 overexpression impairs the interactions of HDAC1 with other NuRD subunits.
HEK-293 cells overexpressing untagged APPL1 at moderate or high levels (m.o.,
moderate overexpression of pAPPL1; h.o., high overexpression of pAPPL1) were subjected
to immunoprecipitation (IP) with anti-HDAC1 or non-speciﬁc rabbit (IgG) antibodies.
Immunoprecipitates along with 10% of the extracts used (input, right panel) were tested
by immunoblottingfor the presence of several NuRD subunits, as indicated. Some non-speciﬁc
binding of APPL1 to IgG-covered Protein G beads is marked with an asterisk. (B) APPL1
overexpression reduces the association of HDAC1 with other NuRD components in the nuclear
fraction. HDAC1 was immunoprecipitated from the nuclear extracts of HEK-293 cells with
endogenous (vector) or overexpressed APPL1. Immunoprecipitates and 5% of the starting
material (input, right panel) were blotted for the presence of the indicated NuRD components.
(C) APPL1 inﬂuences the level of HDAC1 target gene product p21WAF1/CIP1. The level of
p21WAF1/CIP1 expression was analysed by Western blotting using anti-p21 antibody in extracts
of cells with overexpression or silenced expression of APPL1. Left panel: Extracts of HEK-293
cells overexpressing APPL1 (either untagged, pAPPL1, or MYC-tagged, pAPPL1–MYC) or
transfected with a control vector for 48h were immunoblotted as indicated. No efﬁcient
overexpression of APPL1 could be achieved in HeLa cells. Right panel: APPL1 expression was
reduced by esiRNA against APPL1 in HEK-293 or HeLa cells, using esiRNA against luciferase
(luc) as a speciﬁcity control. Transfections with esiRNA were performed for 72h (HEK-293) or
48h (HeLa). The resulting extracts were immunoblotted against APPL1, Myc and p21. GAPDH
was included as a loading control.
nuclear localization of APPL1. However, it is important to
mention that, despite these effects, the association with NuRD
represents only one factor contributing to the nuclear import
of APPL1, because under conditions of HDAC2 silencing when
the APPL1–NuRD binding is not detectable, a certain pool
of APPL1 is still nuclear. It is therefore likely that binding of
APPL1 to other proteins accounts for this localization. Although
to various degrees in different cells, APPL1 appears to be
constitutively present in the nucleus. Its nuclear localization can
be enhanced further via treatment with epidermal growth factor
[16],butwecouldnotdetectanychangesintheextentofAPPL1–
NuRD binding upon such stimulation (results not shown).
Nuclear functions of endocytic proteins – a case of signalling
or moonlighting?
A growing body of evidence indicates that endocytic proteins can
actively participate in the regulation of gene expression, either
by a nuclear translocation in response to a speciﬁc stimulus
or being constitutively present in the nucleus [7,8]. Although
for the majority of endocytic proteins their nuclear functions
remain poorly understood, there are some studies describing
the molecular mechanisms of such phenomena. β-arrestin 1, an
endocytic and signalling adaptor for G-protein coupled receptors,
enters the nucleus upon stimulation of the δ-opioid receptor and
recruitsthehistoneacetyltransferasep300tothepromoterregions
of p27 and c-fos genes [14]. This event enhances local histone
H4 acetylation and transcription, which is further regulated by
an interaction of β-arrestin 1 and the transcription factor CREB
(cAMP-response element-binding protein). HIP1, which acts as
an adaptor in clathrin-mediated endocytosis, can also bind the
androgen receptor. Upon androgen stimulation, HIP1 is recruited
to appropriate DNA-response elements and acts as a positive
regulator of transcription [15]. Also, the heavy chain of clathrin
(in its monomeric form) stimulates p53-mediated transcription
through the recruitment of histone acetyltransferase p300 [11].
In most described cases, it is not clear whether the endocytic
and nuclear pools of such proteins are largely independent or
interchangeable, thus potentially serving as signalling molecules
between the endocytic organelles and the nucleus. The latter
possibility is appealing, considering that histone modiﬁcations
and chromatin remodelling occur in response to extracellular
cues which activate plasma membrane receptors, followed by
endocytosis of ligand–receptor complexes [41,56]. On the other
hand, even if the endocytic and nuclear pools are not linked via a
direct signalling event, the mechanisms determining a particular
nucleocytoplasmic distribution are of importance to secure an
appropriatebalancebetweenthetwofunctions.Futurestudieswill
determine to what extent the interactions of APPL1 with NuRD
and HDAC1 are related to its function on the early endosomes.
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